New hope for tough blood cancers: early trial of ONO-7018 begins

NCT ID NCT05515406

Terminated Disease control Sponsor: Ono Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called ONO-7018 in 9 adults with non-Hodgkin lymphoma or chronic lymphocytic leukemia that had returned or stopped responding to other treatments. The main goal was to find a safe dose and check for side effects. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia lymphoma lymphoma, non-Hodgkin, familial non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL LYMPHOMA, NON-HODGKIN

Contacts and locations

Locations

AMR Kansas City

Kansas City, Missouri, 64114, United States
Baylor Scott & White Research Institute

Dallas, Texas, 75246, United States
Jonsson Comprehensive Cancer Center

Santa Monica, California, 90404, United States
Leo Jenkins Cancer Center/ECU School of Medicine

Greenville, North Carolina, 27858, United States
MD Anderson Cancer Center

Houston, Texas, 77030, United States
Northwest Medical Specialities

Tacoma, Washington, 98405, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Summit Medical Group

Florham Park, New Jersey, 07932, United States
Thomas Jefferson University

Philadelphia, Pennsylvania, 19107, United States
University of Cincinnati

Cincinnati, Ohio, 45267, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.